Dennis Slamon, MD
Hematology & Oncology · Los Angeles, CANPI 1932129533
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,651,630 of the $3,107,315 with a category attached, or 85.3%. Biomarin Pharmaceutical Inc. accounts for 97.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $583,079 and has fallen 96.9% since, to $17,852 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 90 payments — averaging $34,526 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$3M
- Pfizer$44K
- Novartis$38K
- F. Hoffmann-la Roche AG$5K
- Novartis Pharma AG$3K
- Astrazeneca UK Limited$685
- plus $628 from 5 others
Across 55 payments — averaging $7470.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$288K
- Novartis$73K
- AstraZeneca$39K
- F. Hoffmann-la Roche AG$7K
- Novartis Pharma AG$3K
- Seagen Inc.$60
What the payments were for
- Consulting fees$436,33014%
- Speaking & faculty fees$2,651,63085%
- Travel & lodging$16,3091%
- Food & beverage$2,4240%
- Gifts$6220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 39 | $3,016,562 |
| Pfizer(2 entities) | 12 | $43,574 |
| Novartis | 23 | $37,760 |
| F. Hoffmann-la Roche AG | 5 | $4,731 |
| Novartis Pharma AG | 1 | $3,375 |
| Astrazeneca UK Limited | 1 | $685 |
| Gilead | 4 | $335 |
| Daiichi Sankyo Inc. | 2 | $203 |
| Leica Microsystems Inc. | 1 | $40 |
| Genentech, Inc. | 1 | $31 |
| Tesaro, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,107,315 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Los Angeles
- George YaghmourLos Angeles$1.9M
- Kevin KellyLos Angeles$894K
- Raghuveer RanganathanLos Angeles$609K
- Matthew RettigLos Angeles$442K
- David BerzLos Angeles$420K
- Gottfried KonecnyLos Angeles$402K
- Antoni RibasLos Angeles$315K
- Edward GaronLos Angeles$301K
- Rahul NaikLos Angeles$297K
- Sandra HorningStanford$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.